Showing 261 - 280 results of 20,223 for search '(( significant ((i decrease) OR (a decrease)) ) OR ( significant increase decrease ))', query time: 0.70s Refine Results
  1. 261
  2. 262
  3. 263

    HFD decreases intermediate-term memory. by Tong Yue (6033305)

    Published 2025
    “…Error bars indicate SD (n = 3. Student’s <i>t</i>-test, * p < 0.05). (C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”
  4. 264
  5. 265
  6. 266
  7. 267
  8. 268
  9. 269
  10. 270
  11. 271
  12. 272
  13. 273
  14. 274
  15. 275
  16. 276
  17. 277

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 278

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 279
  20. 280